A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

MC Michel, C Foster, HR Brunner, L Liu… - Pharmacological …, 2013 - Elsevier
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in
the treatment of hypertension and heart failure and the protection from diabetic nephropathy …

In silico pharmacology for drug discovery: applications to targets and beyond

S Ekins, J Mestres, B Testa - British journal of pharmacology, 2007 - Wiley Online Library
Computational (in silico) methods have been developed and widely applied to
pharmacology hypothesis development and testing. These in silico methods include …

DrugBank: a knowledgebase for drugs, drug actions and drug targets

DS Wishart, C Knox, AC Guo, D Cheng… - Nucleic acids …, 2008 - academic.oup.com
DrugBank is a richly annotated resource that combines detailed drug data with
comprehensive drug target and drug action information. Since its first release in 2006 …

The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases

HMA Abraham, CM White, WB White - Drug safety, 2015 - Springer
All national guidelines for the management of hypertension recommend angiotensin
receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight …

In silico repositioning of approved drugs for rare and neglected diseases

S Ekins, AJ Williams, MD Krasowski, JS Freundlich - Drug discovery today, 2011 - Elsevier
One approach to speed up drug discovery is to examine new uses for existing approved
drugs, so-called 'drug repositioning'or 'drug repurposing', which has become increasingly …

Design, synthesis, cytoselective toxicity, structure–activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells

H Zhou, S Wu, S Zhai, A Liu, Y Sun, R Li… - Journal of Medicinal …, 2008 - ACS Publications
Ten cytoselective compounds have been identified from 372 thiazolidinone analogues by
applying iterative library approaches. These compounds selectively killed both non-small …

ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques

L Chen, Y Li, Q Zhao, H Peng, T Hou - Molecular pharmaceutics, 2011 - ACS Publications
P-Glycoprotein (P-gp), an efflux transporter, plays a crucial role in drug pharmacokinetic
properties (ADME), and is critical for multidrug resistance (MDR) by mediating the active …

The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so

DB Kell, PD Dobson, E Bilsland, SG Oliver - Drug discovery today, 2013 - Elsevier
A recent paper in this journal sought to counter evidence for the role of transport proteins in
effecting drug uptake into cells, and questions that transporters can recognize drug …

Structure–activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)

Z Dong, S Ekins, JE Polli - Molecular pharmaceutics, 2013 - ACS Publications
The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide
(NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile …

An updated patent review on P-glycoprotein inhibitors (2011-2018)

M Leopoldo, P Nardulli, M Contino… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: P-glycoprotein is a complex ATP-ase transporter involved in physiological and
pathological functions. In particular, it is involved in the onset of multidrug resistance in …